BACKGROUND Acute heart failure (AHF) is a life-threatening disease requiring urgent treatment, including a
Therefore, recent HF guidelines and recommendations emphasized the importance of immediate diagnosis and treatment of patients presenting with AHF (7, 8) . However, this concept has only been evaluated using retrospective data. The REALITY-
AHF (Registry Focused on Very Early Presentation and Treatment in Emergency Department of Acute
Heart Failure) was a prospective multicenter study to evaluate the association between time to treatment and clinical outcome in patients with AHF presenting at the ED.
METHODS
The main objective of REALITY-AHF was to determine the prognostic impact of time to treatments for AHF performed in the acute phase. All consecutive patients with AHF hospitalized through the ED at participating hospitals were enrolled upon the initial hospital admission. Only the first hospitalization during the study period was registered. Patients were included if they were age $20 years and diagnosed with AHF in the ED within 3 h of their first evaluation by caregivers. The AHF diagnosis was made based on Framingham criteria (9) . Exclusion criteria were: 1) treatment with an intravenous (IV) drug before ED arrival; 2) previous heart transplantation; 3) on either chronic peritoneal dialysis or hemodialysis; 4) acute myocarditis; and 5) acute coronary syndrome requiring emergent or urgent revascularization. Patients with missing Btype natriuretic peptide (BNP) or N-terminalproBNP (NT-proBNP) data, and patients with a BNP level <100 pg/ml or NT-proBNP level <300 pg/ml at baseline were also excluded.
Enrollment was performed from August 2014
to December 2015. Among the 20 participating hospitals, 9 were university hospitals and 11 were nonuniversity teaching hospitals.
Because all patients were enrolled at the ED, the time of ED arrival was recorded, and data were collected for up to 48 h from the time of ED arrival.
Drug and doses of all IV treatments were recorded.
Additionally, the time from arrival to the "first IV furosemide" administration was recorded for all patients because it was the primary pre-specified variable of interest. Oral medication taken within 48 h was also recorded for all HF medications, including the amount of diuretics. Baseline physical findings and blood samples were taken and evaluated in the ED for all patients. Echocardiography was performed at the ED and subsequent steady-state phases. Left ventricular ejection fraction was assessed by echocardiography at the ED and categorized into 3 groups: <35%; 35% to 50%; and >50%.
Importantly, the nature of this study did not require participants to use any particular drug or treatment strategy. The mission of the registry was to capture patients with AHF immediately after arrival to the ED and for the study enrollment process to avoid any delay or difference in the time course. With the Guidelines-Heart Failure (GWTG-HF) risk score was calculated for each patient as previously described (10) . The GWTG-HF risk score is based on race, age, systolic blood pressure, heart rate, blood urea nitrogen, sodium levels, and the presence of chronic obstructive pulmonary disease. The discrimination and calibration of this risk score have been well validated in Japanese patients with AHF (11); therefore, the GWTG-HF score was used as an adjustment variable in a multivariable prognostic model. Additionally, the patients were stratified according to GWTG-HF risk score quartiles and quartile groups were evaluated for differences in in-hospital mortality to examine the relationship between GWTG-HF scores at baseline and the prognostic impact of early treatment.
Univariate and multivariable logistic regression analyses were performed to evaluate the association between early treatment and in-hospital prognosis.
Furthermore, generalized estimating equation (GEE) models were used to account for intrainstitutional correlations among patients. The presence of a nonlinear association between D2F time and inhospital mortality was evaluated using a linear regression model with restricted cubic splines of 3, 4, and 5 knots. The goodness-of-fit was compared between models using an analysis of variance test.
To control confounding as much as possible, propensity score matching was also performed as a sensitivity analysis. The propensity score was estimated based on a logistic model constructed with the following variables: age; sex; arrival by ambulance; baseline systolic blood pressure, diastolic blood pressure, heart rate, white blood cell count, hemoglobin, aspartate aminotransferase, alanine aminotransferase, serum sodium, blood urea nitrogen, BNP, and glucose; history of chronic obstructive pulmonary disease; presence/absence of jugular venous distension, orthopnea, peripheral edema, or rales at baseline; and prescription of an angiotensinconverting enzyme inhibitor or loop diuretics at admission. Propensity score matching was performed for the early and nonearly treatment groups with one-to-one caliper matching using a caliper width equal to 20% of the SD of the logit of the calculated propensity score (12) . To assess the performance of the matching, standardized mean differences were calculated for all baseline variables and a difference below 0.1 was considered negligible (i.e., the 2 groups were well balanced) (13). Table 1 .
Patients in the early treatment group were more likely to arrive by ambulance; had acute onset of symptoms, higher blood pressure, and heart rate; and were more likely in sinus rhythm compared with those in the nonearly treatment group. Moreover, the early treatment group showed more signs of conges- The results for the univariate and multivariable linear regression analyses predicting log-transformed D2F time are shown in Online Table 1 and Table 2, respectively. Arriving by ambulance and the presence of signs and symptoms of congestion, including orthopnea, jugular venous distension, angiotensin II receptor blocker prescription at admission, and a high heart rate, were independently associated with a shorter D2F time. In the final multivariable linear regression model, none of the individual covariate variance inflation factors was > 2 and the mean variance inflation factor across all covariates was 1.06. As a sensitivity analysis, we constructed a logistic regression model and GEE model using D2F time as a continuous scale (log D2F time) with an adjustment for GWTG-HF risk score. In both models, the association between log D2F time and in-hospital mortality remained statistically significant (OR: 1.31; 95% CI: Furthermore, we tested the association between early treatment and 30-day mortality from the index hospitalization because there was variability in the length of hospital stay. In this additional sensitivity analysis, early treatment was associated with a lower 30-day mortality; however, the p value did not reach statistical significance in multivariable logistic regression analysis after adjusting for the GWTG-HF risk score or in the propensity score matching analysis ( Table 3 ). Figure 3 shows the association between D2F time and the probability of in-hospital mortality.
Restricted cubic spline modeling with 4 knots was used because this model showed a better goodness- Abbreviations as in Table 1 .
generalizability of these results to all patients with AHF is unclear. Moreover, the use of other IV drugs, such as IV diuretics, was not taken into account in ADHERE, despite the fact that more than 95% of the patients were treated with IV diuretics, predominantly furosemide.
In another study using ADHERE data, an association between the time to administration of the first vasoactive agent and in-hospital mortality was eval- Early treatment resulted in lower mortality overall and stratified by quartiles (Q) of Get with the Guidelines-Heart Failure Score. In-hospital mortality was significantly lower in early treatment group compared to nonearly treatment group (2.3% vs. 6%; p ¼ 0.002).
Early treatment groups consistently showed a lower mortality rate compared with that for the nonearly treatment group across all quartiles, with the absolute risk difference increasing as the Get With the Guidelines-Heart Failure risk score quartile rose.
Matsue et al. The small number of events in our study might lead to the risk of type I error, and study results need to be replicated in future studies. We did not collect data regarding time to laboratory data or time to BNP or NT-proBNP measurement; thus, it is difficult to discriminate between time to diagnosis and time to treatment. Therefore, even with these data, it remains difficult to clearly define the exact time of diagnosis. We do not have data on the respiratory rate or cause of HF exacerbation, which might have an impact on outcomes. Also, an association between D2F time and long-term prognosis should be evaluated in a future study. In Japan, the median length of hospital stay is substantially longer than that for Western countries, which might affect the study results, especially for in-hospital mortality. However, in-hospital mortality was not substantially different between our study cohort and other registries representing American and European patients with AHF (4.0% in ADHERE and 6.7% in EuroHeart Survey II) (20, 21) . Moreover, we obtained a similar association between early treatment and 30-day mortality from the time of the index admission. Because differences in ED systems potentially exist between institutions, our study results might not apply to all institutions. We attempted to adjust for confounders as much as possible by using a risk score that has been validated in Japanese patients with AHF, and showed consistency of our results in sensitivity analyses. Nevertheless, we agree with the possibility that a potential unadjusted confounding could remain, such as a "confounding by indication." Therefore, our study results should be interpreted carefully because there is a considerable possibility that residual confounders remain because The solid blue line represents the estimated probability of in-hospital mortality, the light blue shaded area is 95% confidence interval, and the gray shaded area is a density plot showing the distribution of observed door-to-furosemide time.
there were many differences in patient background between the early and nonearly groups. It should also be noted that D2F time may be associated with prognosis through its association with interinstitutional differences in quality of care for patients with AHF in the ED rather than any direct association with prognosis, although we showed a consistent result in the model accounting for it. Moreover, given its observational nature, it should be noted that only an association, not causality, was demonstrated in the present study. Door-to-diuretics time consists of the time needed to perform evaluation, make a diagnosis, and start intravenous (IV) diuretic therapy after patients with acute heart failure (AHF) arrive at the emergency department (ED). This study showed that mortality increased as the door-to-diuretics time was delayed. 
